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Pentraxins in Complement Activation
and Regulation
Ying Jie Ma* and Peter Garred*
The Laboratory of Molecular Medicine, Department of Clinical Immunology, Section 7631, Rigshospitalet, Faculty of Health
and Medical Sciences, University of Copenhagen, Copenhagen, Denmark
The complement is the first line of immune defense system involved in elimination of
invading pathogens and dying host cells. Its activation is mainly triggered by immune
complexes or pattern recognition molecules (PRMs) upon recognition against non-self
or altered self-cells, such as C1q, collectins, ficolins, and properdin. Recent findings
have interestingly shown that the pentraxins (C-reactive protein, CRP; serum-amyloid
P component, SAP; long pentraxin 3, PTX3) are involved in complement activation and
amplification via communication with complement initiation PRMs, but also complement
regulation via recruitment of complement regulators, for instance C4b binding protein
(C4BP) and factor H (fH). This review addresses the potential roles of the pentraxins in the
complement system during infection and inflammation, and emphasizes the underlining
implications of the pentraxins in the context of complement activation and regulation both
under physiological and pathological conditions.
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INTRODUCTION
The complement system is one of the ancient innate immune defense system, and can
evolutionarily be traced back from the sea urchins (1). In humans, the complement system was
initially discovered in 1895 as a heat-labile effector of antibody-mediated immunity. Since then,
complement has experienced more than 100 years to unveil its authentic features (2). Today,
complement is not only a driver of innate immunity, its functions even extend to additional
physiological and/or pathophysiological roles in immune surveillance and homeostasis far beyond
simple antimicrobial effector functions (3). Complement exerts its functions through effective rules
of activation and regulation under precise control of balance. The part of activation comprises
three routes: the classical pathway (CP), the lectin pathway (LP) and the alternative pathway
(AP) (Figure 1). However, the complement system has the potential to harm the host if it is not
properly controlled and regulated. Therefore, complement activation is precisely modulated in the
circulation and on the healthy host cells by exclusive fluid-phase and cell-bound regulators, which
are crucial in protecting host cells from complement over-activation (Figure 1).
PENTRAXINS: CRP, SAP, AND PTX3
Pentraxins are conserved multifunctional soluble pattern recognition molecules (PRMs)
characterized by a C-terminal pentraxin signature containing a conserved eight amino acid
sequence (13). Proteins of pentraxin family comprise three major members, C-reactive protein
(CRP), serum-amyloid P component (SAP), and pentraxin 3 (PTX3). Based on the primary
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FIGURE 1 | Classical model of complement activation and regulation. Complement activation occurs typically through three routes. Classical pathway activation is
triggered by the C1 complex comprising C1q, C1s, and C1r upon binding to IgM or clusters of IgG against pathogen-associated molecular patterns (PAMPs) or
damage-associated molecular patterns (DAMPs) (4). Lectin pathway activation is induced by soluble pattern recognition molecules (PRMs) mannose-binding lectin
(MBL) upon binding to PAMPs or DAMPs. It is now apparent that the ficolins (ficolin −1,−2, or−3) or collectins (collectin-10, collectin-11 or a heteromeric complex of
collectin-10 and collectin-11) are also involved in lectin pathway activation (5–9). Unlike C1q complexed with the serine proteases C1r and C1s, PRMs involving lectin
pathway activation are often associated with the mannose-binding lectin-associated serine proteases (MASPs). Upon classical and lectin pathway activation, the
serine proteases cleave C4 and C2 to form C3 convertase (C4b·C2a). In contrast, alternative pathway activation occurs by direct tick-over activation of C3 thioester in
solution regardless of trigger, and creates its own C3 convertase (C3b·Bb) when activated C3b covalently bind to the target surfaces in contact with factor B (fB) and
the enzyme factor D (fD) (10, 11). The alternative C3 convertase is highly stabilized when properdin is associated. With release of anaphylatoxin C3a, surface-bound
C3 convertases generate more opsonin C3b, leading to the formation of the classical and lectin pathway C5 convertase (C3b·C4b·C2a) and the alternative C5
convertase (C3b·Bb·C3b). The C5 convertase in turn cleaves C5 into another anaphylatoxin C5a and C5b. Surface-deposited C5b sequentially recruits complement
subunits C6, C7, C8, and C9 on target surface and initiates formation of C5b-9 membrane attack complex (MAC) also named the terminal complement complex (TCC)
which may lead to target lysis (3, 12). The alternative pathway also serves to amplify classical and lectin pathway activation. Fluid-phase and cell-bound regulators
help to modulate complement over-activation; C1 inhibitor (C1-INH) controls the functions of C1r, C1s and MASP-2; C3b and C4b are inactivated by either fluid-phase
factor H (fH)/C4b-binding protein (C4BP) or cell-bound complement receptor type 1 (CR1)/CD46 as cofactors for factor I (fI). Fluid-phase fH/C4BP or cell-bound
CR1/CD55 regulate convertase activity by disassembly through decay-accelerating activity of the regulators. The formation of MAC is controlled by CD59 (3).
structure of the protomer, CRP and SAP are distinguished as the
short pentraxins from the main long pentraxin PTX3 (14). The
genes encoding the short pentraxins (CRP/SAP) and the long
pentraxin (PTX3) are located on chromosome 1q23 and 3q25,
respectively. However, in contrast to the short pentraxins, which
are expressed in liver upon stimulation of inflammatory cytokine,
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the long pentraxin PTX3 is produced by diverse immune cells,
such asmacrophages, neutrophils, dendritic cells, and endothelial
cells (15). CRP is one of the major acute phase proteins in human,
and its level in plasma elevates by 1,000-fold via stimulation
of hepatocytes by acute phase stimulus. By contrast, PTX3
is barely detectable in human blood circulation (< 2 ng/ml)
under physiological conditions, while the serum level drastically
increases (200–800 ng/ml) within 6–8 h during infection and
inflammation (15). The pentraxins share the conserved C-
terminal pentraxin domain, whereas PTX3 harbors a unique
N-terminal region without sequence homology to any known
proteins so far (15).
The pentraxins recognize wide spectrum of microbial
moieties to mediate opsonophargocytosis, but also interact
with extracellular matrix (ECM) proteins to stabilize ECM
deposition and modified self-structures on dying host cells to
keep homeostasis (14). Concerning the antibody-like common
features conserved in evolution, the pentraxins mediate
phagocytosis and inflammation by macrophages via interaction
with the surface Fcγ receptors upon target opsonization (16–18).
Thus, the pentraxins are important for both innate immune
defense and tissue homeostasis (13, 14, 19).
PENTRAXINS-MEDIATED COMPLEMENT
CROSS-ACTIVATION
Decades of initial research have solidified complement
activation by three separate and autonomous routes as
described in Figure 1. The CP and LP activation are mainly
mediated by exclusive PRMs upon opsonization. Apart
from immunoglobulins and several other ligands the CP
is also activated via the antibody-like common features
of the pentraxins, where CRP, SAP, and PTX3 instead of
immunoglobulins recruit C1 complexes upon binding to target
surfaces (16, 20, 21). Following antigen stimulation, antibody
production often experiences complexity of multiple process
by B-cells via differentiation and proliferation and antibody
interaction is highly dependent on its antigen specificity. In
contrast, the pentraxins are either acute phase reactants under
infectious and inflammatory conditions or present constitutively
with invariant and high level, and broadly recognize the
common pattern moieties arising from microorganisms.
Therefore, pentraxins-mediated immune responses are often
mobilized rapidly and drastically in resistant to microbial
invasion and tissue damage, acting at systemic and local
tissue level. Although the antibody-like features have been
endowed with the pentraxins in evolution, it is still deficient in
antigen-exclusive antibody specificity. Considering complement
activation and the underlying functional consequences,
pentraxin-mediated initiation is much more rapid and efficient
than antibody-dependent responses during infection at early
stage (14).
As has been shown for C1q it has recently been shown
that the pentraxins interact with some of the PRMs from
LP, thus allowing CRP, SAP, and PTX3 to effectively dock at
certain bacteria through sensory inputs due to their spontaneous
defect in opsonization toward it (22). The interaction has been
shown to specifically elevate host immune defense via the
LP of complement activation against various microorganism
including bacteria and fungi, thus adapting to tricky pathogenic
conditions (22). More importantly, the CP and LP, which
were previously defined separate and autonomous, have been
demonstrated to establish cross-communication through the
interaction between the pentraxins and LP PRMs, enabling
amplification of complement activation and its concomitant anti-
microbial activity (23). In this respect, it should be emphasized
that the interaction between the pentraxins and LP PRMs not
only serves to boost complement activation, may also result in
broadening repertoire of pattern recognition and complement-
mediated effector functions via such synergistic effects (24).
The pentraxins are capable of selectively opsonizing certain
bacteria, fungi, and viruses (25), but not Candida albicans and
Burkholderia cepacia (26). However, the purified pentraxins
(PTX3 and SAP in particular, but not CRP) could bind to
Candida albicans only in the premise of presence of human
serum (27), implying that the presence of certain human serum
factor might enable anchorage of the pentraxins on Candida
albicans indirectly. Recent findings have shown that serum MBL
docks both PTX3 and SAP to Candida albicans, and that this
interaction enhances complement activation and the subsequent
opsonophagocytosis by polymorphonuclear leukocytes (PMN)
(27). Interaction of PTX3 with MBL leads to communication
between the LP and CP via C1q, whereas it is still enigma
how SAP:MBL complexes boost complement activation. These
findings suggest that crosstalk between the pentraxins and MBL
provides two potential complement amplification mechanisms
via cross-activation within the complement system (Figure 2).
It has been well documented that the complement system
plays a non-redundant role against Aspergillus fumigatus
infection (29). The state of complement deficiency is highly
susceptible to Aspergillus fumigatus infection and mice deficient
in C5 has been shown to be hardly survived (30, 31). Ficolin-
2 has been recently suggested to serve as a particular inducer
of anti-fungal activity through provoking the LP of complement
activation and/or regulating pro- and anti-inflammatory airway
immune responses in treatment of Aspergillus fumigatus
challenge (24, 32, 33). Ficolin-2 has been shown to recognize
Aspergillus fumigatus in a Ca2+-insensitive manner with stronger
binding at acidic pH (34, 35), which typically prevails in a
local infectious and inflammatory condition (36) and is required
to boost complement activity (37). Zhang et al. previously
reported that interaction of CRP with ficolin-2 is elevated in
an acidic pH-sensitive manner (23). These data suggest that
local prevalence of acidic circumstances may be essential to
trigger reciprocal interaction between ficolin-2 and CRP to
combat Aspergillus fumigatus at the early stage of infection.
Consistent with the previous reports, analysis of bronchoalveolar
lavage (BAL) fluid has attested presence of ficolin-2 in invasive
aspergillosis (IA)-suffering patients, and demonstrated a notable
roles of ficolin-2 in modulation of alveolar immune responses
against infection of Aspergillus fumigatus (35). In agreement
with those reports, Genster et al. recently found that mice
are vulnerable to fungal infection under the ficolin-deficient
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FIGURE 2 | Pentraxins-expanded network of complement activation and regulation. Classical pathway (CP) activation mainly occurs by immune complexes, but also
mediated through antibody-like features of the pentraxins in complex with C1q. In addition to the traditional activating fashion as depicted above, lectin pathway (LP)
is also indirectly activated by PTX3, CRP, or SAP upon recruitment of MBL or the ficolins. Cross-activation of the CP and LP initiates when heterocomplexes are
created on target surfaces between PTX3 (or CRP) and MBL (or ficolin-2) and C1q. Two additional activation pathways emerge to boost complement amplification.
The amplification pathways comprise the avenue open to the sequence below: target→ PTX3 (or CRP)→ ficolin-2/MASPs→ C4→ C3→ formation of membrane
attach complex (MAC) (amplification 1); target→ MBL (or ficolin-2/MASPs)→ PTX3 (or CRP)→ C1q→ C4→ C3→ formation of MAC (amplification 2) (3). Alternative
pathway (AP) activation often occurs independently regardless of trigger by spontaneous C3 activation in solution, and rapidly propels nascent C3b binding to nearby
target surfaces covalently. In addition, it is hypothesized that surface-bound collectin-12 (CL-12) mediates CP activation by crosstalk with PTX3, CRP or SAP. A recent
emerging activation avenue follows relatively specific sequence that involves pattern recognition and opsonization by soluble CL-12→ recruitment of properdin→ de
novo C3 convertase assembly→ C3 amplification loop→ generation of downstream effector molecules→ induction of immune signaling (28). Despite its diverse
avenues, overarching concept of complement activation focuses on sensing and eliminating potential danger signals through immunesurveillance and immune effector
mechanisms. The pentraxins recognize major fluid-phase complement regulators, C4BP and fH, resulting in down-regulation of complement-mediated inflammation.
condition (38). These results suggest that serum ficolin-2 may
facilitate to elevate host immune responses at local sites of
pulmonary fungal infection via transmigration to alveoli and
thus play a crucial role in lung infection (35). Mice deficient in
PTX3 have shown increased susceptibility to invasive pulmonary
aspergillosis (IPA) and accelerated death compared with mock
control, which was attributed to the defect in fungicidal activities
against IPA in regard to opsonophagocytosis and activation of an
adaptive type 2 responses (39). In parallel with those evidences,
Cunha et al. intriguingly found a PTX3 single-nucleotide
polymorphisms (SNPs) in donors with a homozygous haplotype,
leading to increased vulnerability to invasive aspergillosis when
patients receives hematopoietic stem-cell transplantation from
such donors (39). These results suggest that PTX3 plays non-
redundant roles in antifungal immunity. In this respect, it should
be noted that collaboration of liver-derived CRP and immune
cell-expressed PTX3 with migratory ficolin-2 might also further
boost the microbicidal immune responses at systemic and local
tissue level, respectively, for instance through the complement
cross-activation and amplification mechanisms.
Recently, the pentraxins have been shown to interact
with CL-12, a newly identified scavenger receptor C-type
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lectin (SRCL) (40, 41). By using ELISA and CHO/ldlA7 cell lines
expressing transmembrane CL-12 as platform, the interaction of
the pentraxins with transmembrane CL-12 has been visualized.
It was shown a propensity of the pentraxins including CRP,
SAP, and PTX3 for direct binding of CL-12, and demonstrated
that the interaction is able to result in the CP of complement
activation via recruitment of C1q on HEK293 cell lines
expressing transmembrane CL-12 (42). However, whether this
is indeed a case on native CL-12-expressing primary cells,
for instance HUVEC or HUAEC, is still awaiting further
clarification. Nevertheless, a soluble form of CL-12 has recently
been identified and revealed to trigger AP of complement
activation through direct contact with properdin (28). Whether
the pentraxins interact with soluble form of CL-12 and expand
a novel complement crosstalk against invading pathogens is still
unknown.
PENTRAXINS IN COMPLEMENT
REGULATION
In general, complement activation is precisely modulated in the
circulation and on healthy host cells by exclusive soluble and cell-
bound regulators as described in Figure 1. Recent data show that
the pentraxins surveil and modulate the action of complement to
avoid overwhelming activation via interaction with complement
negative regulators. Like CRP and SAP, PTX3 is able to bind
the main fluid-phase regulator of the CP and LP C4BP. Similar
to the short pentraxins, PTX3 in solution preserve the cofactor
activity of C4BP for fI upon complex formation (43). When
anchored on apoptotic/necrotic cells and extracellular matrix
(ECM), PTX3 is capable of recruiting functionally active C4BP,
leading to complement C4b inactivation and reduced terminal
complement complex (TCC) deposition on the surfaces. Both
CRP and PTX3 have been observed to interact with fH, the main
soluble regulator of the AP, and the two PTX3 binding sites on fH
were defined to be located on fH short consensus repeat (SCR) 7
and SCR19-20 (44), of which the former is also employed for CRP
binding in addition to SCR8-11 (45, 46). fH was found to remain
its C3 inhibitory activity upon binding to the pentraxins, thus
preventing exaggerated AP mediated complement activation on
CRP or PTX3-immobilized surfaces. Therefore, the pentraxins
may target all the complement pathways by interaction with
C4BP and fH and they may assist in regulation of complement
activation to avoid the adverse effect of complement in tissues.
Mutations or polymorphisms of fH are associated with
the pathogenesis of various inflammatory human diseases, for
instance atypical hemolytic uremic syndrome (aHUS) and age-
related macular degeneration (AMD) due to dysregulation of
the AP. Interestingly, Tyr402His (a polymorphic amino acid
variant in SCR7 of fH), which is linked to high risk of aHUS
and AMD, influences the binding of CRP, but not PTX3-fH
interaction. Therefore, reduced CRP- fH Tyr402His interaction
might be involved in pathogenesis of the diseases due to
the complement-mediated increased inflammation, where PTX3
could compensate for these changes at the site of inflammation.
Kelly et al. previously showed that heparin sulfate inhibits the
AP through interaction with fH, and found that fH-mediated
C3b inactivation is highly dependent on heparin sulfate and
the degree of sulphation in the Bruch’s membrane (BrM) (47).
Thus, BrM/choroid, a site of tissue damage expressing abundant
heparin sulfate glycosaminoglycans in AMD, might be protected
by recruitment of fH under normal conditions. In addition, PTX3
stored inside BrM might also act as a second line protection
for mobilization of fH and modulate complement activation.
Given the following facts that (1) the binding site for heparin
on fH is overlapped with PTX3 to SCR19-20; (2) fH Tyr402His
influences the binding of heparin as compared with its wild type;
(3) PTX3 binds equally to both the variant and the wild type,
the state of PTX3 deficiency would impact on the patients more
with fH Tyr402His than its wild type, since the decline in fH
binding to heparin would not be supplied by reserved PTX3.
In this respect, it is worthy to note that since PTX3 is rapidly
and dramatically expressed as an acute phase reactant in the
retinal pigmented epithelium (RPE) in response to inflammatory
stimuli, the manifestations of fH Tyr402His might be veiled in
AMD. Interestingly, it has been recently substantiated that PTX3
serves to brake the complement and the subsequent NLRP3
inflammasome activation through regulation of fH in the RPE
(48).
Malignant cells have been previously shown to be monitored
and recognized by the complement system and the concomitant
complement activation often occurs in many cancers upon
recognition (49). However, the complement system has also been
suggested to have a role in the development of tumor promoting
inflammation and the intermediate product of complement
activation C5a has been shown to play a tumor-exacerbating
role via elevation of T cell suppression effect and CCL-2
production attracting tumor-associated macrophages (TAMs)
and favoring M2-like polarization by bone marrow-derived
suppressor cells (50, 51). PTX3 has recently been shown to
contribute in regulation of tumor growth, which was attributed
to its capacity in control of tumor promoting inflammation
through coordination with complement regulator fH (52). As
such PTX3 does seem to have a direct effect on tumor cell growth.
However, PTX3 deficient animals were more susceptible to
chemically induced mesenchymal and epithelial carcinogenesis
than control animals (52). PTX3 deficient tumors showed
enhanced complement C3 deposition and C5a levels, CCL2
production, and tumor-promoting macrophage recruitment,
which was attributed to dysregulated complement activation
since C3-genetic inactivation and CCL2 inhibition reverted the
phenotype and the increased susceptibility to mesenchymal
carcinogenesis in PTX3-deficient mice. These findings suggest
a crucial role of PTX3 in complement-dependent tumor-
related inflammation probably via fH recruitment. Lack of the
functional PTX3 and/or fH might exacerbate pathophysiological
consequences during tumor growth and development due to
complement dysregulation.
Apart from being a serum marker of systemic inflammation
CRP is also suggested to have a direct pathological role in tissues
in diseases, such as AMD (53, 54). CRP exists primarily in
two forms with distinct structure and biological activity, the
native pentameric CRP (pCRP) and monomeric CRP (mCRP),
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and circulates in the blood stream as a non-covalent, anti-
inflammatory pCRP, however when dissociated into mCRP upon
binding to certain cell and matrix surfaces, it becomes rather
pro-inflammatory (55). Given the findings that the majority
of CRP found in BrM is in monomeric form, although pCRP
will still be present in the blood vessels of the choroid in
vivo (53), mCRP is likely a tissue-associated form derived from
circulating pCRP. Accumulating evidences show that if fH is
dysfunctional mCRP activates the complement at retina/choroid
interface and leads to exacerbate chronic inflammation and
subsequent tissue damage (56), indicating the pivotal role of
pro-inflammatory mCRP-mediated complement activation and
regulation in normal conditions. In addition, fH has been shown
to interact with mCRP through its binding sites located in SCR
6-8 and SCR 19-20 regions, but not with pCRP (46, 57–61).
CONCLUDING REMARKS
The complement system is a double-edged sword, one toward to
eliminate danger signals and hostile intruders, while the other
is toward healthy self, which may lead to pathological situations
if it is not controlled properly. The pentraxins are involved in
both complement activation and regulation via crosstalk with
major complement initiating molecules (C1q, ficolin-2, MBL,
and CL-12) as well as complement regulators (C4BP and fH)
(Figure 2). The crosstalk events between the pentraxins and
the CP and LP PRMs have been recently highlighted for their
amplifying roles in immunosurveillance, anti-microbial immune
responses, and immunologic homeostasis. However, evidence
suggests immunopathogenicity of those cooperative events
in infectious inflammation if activated inappropriately, and
also emphasizes the potential deleterious impact on pathogen
immune evasion and development of complement-related
diseases. The pathogenic side of the potential functional
roles of PRM heterocomplexes and their involvement in
complement activation need to be further explored: whether
PRM heterocomplexes are involved in potent inducers of
immunopathology during infection and inflammation and how
it exacerbates disease severity are both intriguing unanswered
questions. Furthermore, recent work has focused on how the
pentraxins-mediated complement activation and regulation
influences and thus contributes to chronic inflammation,
which likely constructs a microenvironment for initiation and
development of complement-mediated pathology. Emerging
evidences discussed above reinforce the importance of the
pentraxins (CRP and PTX3 in particular) in complement
activation and regulation in the pathogenesis of age-associated
diseases and complement-dependent tumor-promoting
inflammation. Given the recent findings that novel collectin
11 or properdin-directed complement activation triggers acute
kidney injury, it is also interesting to determine whether and
how the pentraxins regulate or exacerbate complement-involved
renal injury upon complex formation with the inducers of
renal injury. After many years’ success of complement drug
applications in the treatment of complement-related diseases (ex.
PNH and aHUS), the future of the complement field becomes
much brighter and many of complement drugs are being
processed in preclinical and clinical stages of development in
current years. Pentraxins are recently positioning with renewed
focus as a novel therapeutic targets being explored in the
community of drug development. Importantly, anti-pentraxins
drugs (CPHPC and dezamizumab) targeting human SAP
have recently entered in clinical phase 2 trial for treatment of
amyloidosis and Alzheimer’s disease, and human CRP inhibitor
targeting CRP-driven complement activation-mediated tissue
damage is also being developed (62). Taken together, a better
understanding of the complex roles of the pentraxins in the
complement system and its involvement in human inflammatory
diseases will direct more promising options of therapy against
the consequences of certain pathogen infection, and possibly
certain complement-related inflammatory diseases.
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